Is randomized trial of neoadjuvant chemotherapy of ovarian cancer necessary?

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 371-

  Bose, Chinmoy K ^a  

^a Netaji Subhash Chandra Bose Cancer Research Institute   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LETTER; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67649286660     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.03.037     Document Type: Letter

References (2)

1. Onda T., Kobayashi H., Nakanishi T., Hatae M., Iwasaka T., Konishi I., Shibata T., Fukuda H., Kamura T., Yoshikawa H., and Japan Clinical Oncology Group Study JCOG0206. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers. Gynecol Oncol. (2009 Jan 30) [Electronic publication ahead of print]
2. Schwartz P.E. What is the role of neoadjuvant chemotherapy in the management of ovarian cancer?. Oncology (Williston Park) 22 10 (2008 Sep) 1118-1125 discussion 1130, 1132, 1134